Company intelligence

ZEAL

Zealand Pharma A/S · NASDAQ · Healthcare

Price$17.59+0.00% · +$0.00

Market cap0Equity value

P / E0.0Trailing ratio

Volume2.16KLatest session

Market data

ZEAL price chart

TradingView

Related signals

1 min delayed

Browse public ZEAL signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ZEALJun 5, 20260.00% since signal

Zealand Phase 2 petrelintide data strengthens obesity therapy outlook

Zealand Pharma announced additional Phase 2 ZUPREME-1 data on petrelintide at ADA 2026, showing up to 10.7% weight loss at Week 42 versus placebo with tolerability similar to placebo. Phase 3 trials are planned to begin in H2 2026, and Roche has endorsed co-development and co-commercialization, potentially unlocking significant upside for ZEAL’s obesity/metabolic health program.

View signal analysis

ZEALMar 13, 20250.00% since signal

Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall. - MarketWatch

Roche partners with Zealand Pharma for a $5.3 billion weight-loss drug deal. Petrelintide, a weekly injection, targets better tolerability compared to existing drugs. Zealand Pharma shares surged 29% in response to the deal announcement. Analysts view Roche as a beneficial partner for Zealand Pharma's ambitions. Potential drug launch timeframe estimated around 2029.

View signal analysis

Research